Introduction
Material and methods
Results
MeSH and GO terms | Papers labeled with the term |
---|---|
Cluster 1 | |
Doxorubicin | 58 |
Liposomes | 58 |
Pharmaceutical preparations | 45 |
Animals | 38 |
Neoplasms | 32 |
Cluster 2 | |
Doxorubicin | 57 |
Liposomes | 57 |
Humans | 50 |
Patients | 44 |
Female | 44 |
Neoplasms | 41 |
Adult | 35 |
Middle aged | 35 |
Therapeutics | 30 |
Aged | 29 |
Drug carriers | 29 |
Cluster 3 | |
Liposomes | 50 |
Doxorubicin | 48 |
Cells | 40 |
cell | 40 |
Animals | 38 |
Pharmaceutical preparations | 37 |
Mice | 36 |
Humans | 35 |
Neoplasms | 31 |
Cluster 4 | |
Liposomes | 33 |
Doxorubicin | 30 |
Pharmaceutical preparations | 30 |
Neoplasms | 27 |
Animals | 27 |
Therapeutics | 24 |
Drug Carriers | 22 |
Mice | 22 |
Humans | 19 |
Cluster 5 | |
Doxorubicin | 34 |
Liposomes | 34 |
Pharmaceutical preparations | 28 |
Animals | 25 |
Neoplasms | 25 |
Temperature | 18 |
Cluster 6 | |
Doxorubicin | 16 |
Humans | 16 |
Liposomes | 15 |
Patients | 14 |
Male | 14 |
Middle aged | 12 |
Aged | 12 |
Female | 12 |
Treatment outcome | 11 |
Polyethylene glycols | 9 |
Therapeutics | 9 |
Adult | 9 |
Cluster 7 | |
Doxorubicin | 10 |
Liposomes | 10 |
Patients | 9 |
Humans | 9 |
Female | 8 |
Breast neoplasms | 8 |
Survival | 7 |
Neoplasms | 7 |
Therapeutics | 7 |
Aged | 7 |
Adult | 6 |
Middle aged | 6 |
Safety | 6 |
Cluster 8 | |
Doxorubicin | 9 |
Liposomes | 9 |
Patients | 9 |
Recurrence | 9 |
Survival | 9 |
Adult | 9 |
Aged | 9 |
Female | 9 |
Humans | 9 |
Middle aged | 9 |
Ovarian neoplasms | 9 |
Platinum | 8 |
Polyethylene glycols | 8 |
Disease-free survival | 7 |
Neoplasms | 7 |
Safety | 6 |
Aged, 80 and over | 6 |
Position | Authors | Citation | Title |
---|---|---|---|
Cluster 1 | |||
The first by degree | Mayer, L D, Tai, L C, Ko, D S, Masin, D, Ginsberg, R S, Cullis, P R, Bally, M B | Cancer research (Cancer Res), Vol. 49 (21): 5922–30, 1989 | Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. |
Second by degree | Mayer, L D, Tai, L C, Bally, M B, Mitilenes, G N, Ginsberg, R S, Cullis, P R | Biochimica et biophysica acta (Biochim Biophys Acta), Vol. 1025 (2): 143–51, 1990 | Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. |
Second by degree | Herman, E H, Rahman, A, Ferrans, V J, Vick, J A, Schein, P S | Cancer research (Cancer Res), Vol. 43 (11): 5427–32, 1983 | Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. |
The first by hierarchy | Forssen, E A, Tökès, Z A | Proceedings of the National Academy of Sciences of the United States of America (P Natl Acad Sci Usa), Vol. 78 (3): 1873–7, 1981 | Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. |
Cluster 2 | |||
The first by degree | Muggia, F M, Hainsworth, J D, Jeffers, S, Miller, P, Groshen, S, Tan, M, Roman, L, Uziely, B, Muderspach, L, Garcia, A, Burnett, A, Greco, F A, Morrow, C P, Paradiso, L J, Liang, L J . | Journal of clinical oncology: official journal of the American Society of Clinical Oncology (J Clin Oncol), Vol. 15 (3): 987–93, 1997 | Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. |
Second by degree and first by hierarchy | Gabizon, A, Catane, R, Uziely, B, Kaufman, B, Safra, T, Cohen, R, Martin, F, Huang, A, Barenholz, Y | Cancer research (Cancer Res), Vol. 54 (4): 987–92, 1994 | Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. |
Second by degree | Uziely, B, Jeffers, S, Isacson, R, Kutsch, K, Wei-Tsao, D, Yehoshua, Z, Libson, E, Muggia, F M, Gabizon, A | Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol), Vol. 13 (7): 1777–85, 1995 | Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. |
Cluster 4 | |||
The first by degree and first by hierarchy | Papahadjopoulos, D, Allen, T M, Gabizon, A, Mayhew, E, Matthay, K, Huang, S K, Lee, K D, Woodle, M C, Lasic, D D, Redemann, C | Proceedings of the National Academy of Sciences of the United States of America (P Natl Acad Sci Usa), Vol. 88 (24): 11460–4, 1991 | Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. |
Second by degree | Vaage, J, Mayhew, E, Lasic, D, Martin, F | International journal of cancer. (Int J Cancer), Vol. 51 (6): 942–8, 1992 | Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. |
Cluster 3 | |||
The first by degree | ElBayoumi, Tamer A, Torchilin, Vladimir P | Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res), Vol. 15 (6): 1973–80, 2009 | Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. |
Second by degree | Garde, Seema V, Forté, André J, Ge, Michael, Lepekhin, Eugene A, Panchal, Chandra J, Rabbani, Shafaat A, Wu, Jinzi J | Anti-cancer drugs (Anti-cancer Drug Des), Vol. 18 (10): 1189–200, 2007 | Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. |
The first by hierarchy | Lee, R J, Low, P S | Biochimica et biophysica acta (Biochim Biophys Acta), Vol. 1233 (2): 134–44, 1995 | Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. |
Cluster 5 | |||
The first by degree | Kong, G, Anyarambhatla, G, Petros, W P, Braun, R D, Colvin, O M, Needham, D, Dewhirst, M W | Cancer research (Cancer Res), Vol. 60 (24): 6950–7, 2000 | Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. |
Second by degree | Needham, D, Anyarambhatla, G, Kong, G, Dewhirst, M W | Cancer research (Cancer Res), Vol. 60 (5): 1197–201, 2000 | A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. |
The first by hierarchy | Mayhew, E G, Goldrosen, M H, Vaage, J, Rustum, Y M | Journal of the National Cancer Institute (J Natl Cancer I), Vol. 78 (4): 707–13, 1987 | Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. |
Cluster 6 | |||
The first by degree and first by hierarchy | Northfelt, D W, Martin, F J, Working, P, Volberding, P A, Russell, J, Newman, M, Amantea, M A, Kaplan, L D | Journal of clinical pharmacology (J Clin Pharmacol), Vol. 36 (1): 55–63, 1996 | Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. |
Second by degree | Hussein, Mohamad A, Wood, Laura, Hsi, Eric, Srkalovic, Gordan, Karam, MaryAnn, Elson, Paul, Bukowski, Ronald M | Cancer, Vol. 95 (10): 2160–8, 2002 | A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. |
Cluster 7 | |||
The first by degree | Batist, G, Ramakrishnan, G, Rao, C S, Chandrasekharan, A, Gutheil, J, Guthrie, T, Shah, P, Khojasteh, A, Nair, M K, Hoelzer, K, Tkaczuk, K, Park, Y C, Lee, L W . | Journal of clinical oncology: official journal of the American Society of Clinical Oncology (J Clin Oncol), Vol. 19 (5): 1444–54, 2001 | Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. |
Second by degree | Harris, Lyndsay, Batist, Gerald, Belt, Robert, Rovira, Douglas, Navari, Rudolph, Azarnia, Nozar, Welles, Lauri, Winer, Eric, TLC D-99 Study Group . | Cancer, Vol. 94 (1): 25–36, 2002 | Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. |
The first by hierarchy | Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. | Cancer Chemother Pharmacol. 1989;23(2):81–6. | Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. |
Cluster 8 | |||
The first by degree and first by hierarchy | Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. | J Clin Oncol. 2001 Jul 15;19(14):3312–22. | Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. |
Second by degree | Gordon, Alan N, Tonda, Margaret, Sun, Steven, Rackoff, Wayne, Doxil Study 30–49 Investigators | Gynecologic oncology (Gynecol Oncol), Vol. 95 (1): 1–8, 2004 | Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer |
Cluster 1 | Hadassah Medical Organization, Israel. | 6 |
British Columbia Cancer Agency, Canada. | 5 | |
Georgetown University, USA. | 5 | |
Hiroshima University, Japan. | 3 | |
University of British Columbia, Canada. | 3 | |
No information | 14 | |
Cluster 2 | University of Southern California, USA. | 5 |
Hadassah Medical Organization, Israel. | 5 | |
New York University, USA. | 3 | |
SEQUUS Pharmaceuticals, Inc., Menlo Park, USA. | 3 | |
University of Alberta, Canada. | 3 | |
Cluster 3 | University of Alberta, Canada. | 10 |
Hadassah Medical Organization, Israel. | 4 | |
Northeastern University, USA. | 3 | |
Peking University, China. | 3 | |
Cluster 4 | Hadassah Medical Organization, Israel. | 10 |
Roswell Park Cancer Institute, USA. | 8 | |
Cluster 5 | Duke University, USA. | 7 |
Harvard Medical School, USA. | 6 | |
University of California-San Francisco, USA | 3 | |
Cluster 6 | Cleveland Clinic Foundation, USA. | 3 |
Cluster 7 and 8 | All institution have just one paper in theses clusters | 1 |